

LEARNING OBJECTIVES

11-30-21

PERFORMANCE GAP/ ACTIVITY NEED: 71% of all cancer deaths occur outside of the 5 currently available standard screening tests. There is a need for identification of multiple cancer risk at once in an efficient, highly sensitive test.

Emerging technologies leverage cell free DNA analysis for detection of cancer in blood and machine learning to improve cancer origin make “liquid biopsy” a feasible approach to multi cancer screening for the first time [OKGordon, personal communication, 11/29/21]. It is important for primary care physicians to be knowledgeable about this concept, explain it to their patients, and relay the importance of genetic testing for high-risk patients.

DESIRED OUTCOMES: At the end of the activity, attendees will be able to:

- describe the technology that underlies the current multi cancer “liquid biopsies”.
- identify patients who are eligible and would most benefit from an MCED.
- compare the approaches of single cancer screening versus multi cancer detection strategies.

LEARNERS: all clinicians

DESIRABLE PHYSICIAN ATTRIBUTE: apply evidence-based practice, provide patient-centered care